AI assistant
Sending…
BIOGEN INC. — Director's Dealing 2011
Nov 3, 2011
30291_dirs_2011-11-03_b68b9b4e-3e2c-4ed2-bfc1-a399dbe21e3b.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BIOGEN IDEC INC. (BIIB)
CIK: 0000875045
Period of Report: 2011-11-01
Reporting Person: Cox John (EVP Pharmaceutical Oper & Tech)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2011-11-01 | Common Stock | M | 2175 | $72.87 | Acquired | 11763.0295 | Direct |
| 2011-11-01 | Common Stock | S | 2175 | $114.37 | Disposed | 9588.0295 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2011-11-01 | Stock Option (Right to Buy) | $72.87 | M | 2175 | Disposed | 2017-11-01 | Common Stock (2175) | Direct |
Footnotes
F1: Exercise/sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934.
F2: The stock options vest in four (4) equal annual installments commencing one year after the grant date of 11/1/2007.
More from BIOGEN INC.
Regulatory Filings
2026
May 14
Major Shareholding Notification
2026
May 6
Major Shareholding Notification
2026
Apr 29
Interim / Quarterly Report
2026
Apr 29
Regulatory Filings
2026
Apr 29
Annual Report
2026
Apr 28
Proxy Solicitation & Information Statement
2026
Apr 28
Proxy Solicitation & Information Statement
2026
Apr 28
Major Shareholding Notification
2026
Apr 7
Regulatory Filings
2026
Apr 6